JP2021533777A5 - - Google Patents

Info

Publication number
JP2021533777A5
JP2021533777A5 JP2021507743A JP2021507743A JP2021533777A5 JP 2021533777 A5 JP2021533777 A5 JP 2021533777A5 JP 2021507743 A JP2021507743 A JP 2021507743A JP 2021507743 A JP2021507743 A JP 2021507743A JP 2021533777 A5 JP2021533777 A5 JP 2021533777A5
Authority
JP
Japan
Prior art keywords
tcr
seq
amino acid
nucleic acid
recombinant nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046876 external-priority patent/WO2020037239A1/en
Publication of JP2021533777A publication Critical patent/JP2021533777A/ja
Publication of JP2021533777A5 publication Critical patent/JP2021533777A5/ja
Priority to JP2024035703A priority Critical patent/JP2024060024A/ja
Pending legal-status Critical Current

Links

JP2021507743A 2018-08-16 2019-08-16 T細胞受容体構築物およびその使用 Pending JP2021533777A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024035703A JP2024060024A (ja) 2018-08-16 2024-03-08 T細胞受容体構築物およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862764817P 2018-08-16 2018-08-16
US62/764,817 2018-08-16
US201962810112P 2019-02-25 2019-02-25
US62/810,112 2019-02-25
PCT/US2019/046876 WO2020037239A1 (en) 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024035703A Division JP2024060024A (ja) 2018-08-16 2024-03-08 T細胞受容体構築物およびその使用

Publications (2)

Publication Number Publication Date
JP2021533777A JP2021533777A (ja) 2021-12-09
JP2021533777A5 true JP2021533777A5 (cg-RX-API-DMAC7.html) 2022-08-29

Family

ID=69525945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507743A Pending JP2021533777A (ja) 2018-08-16 2019-08-16 T細胞受容体構築物およびその使用
JP2024035703A Pending JP2024060024A (ja) 2018-08-16 2024-03-08 T細胞受容体構築物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024035703A Pending JP2024060024A (ja) 2018-08-16 2024-03-08 T細胞受容体構築物およびその使用

Country Status (14)

Country Link
US (1) US12331097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837279A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021533777A (cg-RX-API-DMAC7.html)
KR (1) KR20210074277A (cg-RX-API-DMAC7.html)
CN (2) CN112888707B (cg-RX-API-DMAC7.html)
AU (2) AU2019321608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002826A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109232A1 (cg-RX-API-DMAC7.html)
IL (1) IL280718B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001837A (cg-RX-API-DMAC7.html)
PH (1) PH12021550307A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101524RA (cg-RX-API-DMAC7.html)
TW (1) TW202021982A (cg-RX-API-DMAC7.html)
WO (1) WO2020037239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
AU2019321608B2 (en) 2018-08-16 2024-07-25 Biontech Us Inc. T cell receptor constructs and uses thereof
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CA3187028A1 (en) * 2020-06-17 2021-12-23 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptides and uses thereof
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
WO2022036103A1 (en) * 2020-08-13 2022-02-17 Rootpath Genomics, Inc. Compositions and methods for antigen identification
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ras突然変異体エピトープペプチドおよびras突然変異体を認識するt細胞受容体
WO2022158977A1 (en) * 2021-01-21 2022-07-28 Erasmus University Medical Center Rotterdam T cells for use in therapy
JP2024512808A (ja) * 2021-04-05 2024-03-19 ヤンセン バイオテツク,インコーポレーテツド Calr及びjak2t細胞受容体
KR20240007162A (ko) * 2021-04-14 2024-01-16 티스캔 테라퓨틱스, 인크. Magec2 면역원성 펩티드, magec2 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도
US20240190940A1 (en) * 2021-04-21 2024-06-13 The United States of America, as represented by the Secretary, Department of Health and Human Serice Hla class i-restricted t cell receptors against ras with q61k mutation
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023220718A1 (en) * 2022-05-13 2023-11-16 Fred Hutchinson Cancer Center Binding proteins specific for ras neoantigens and uses thereof
TW202402798A (zh) * 2022-05-23 2024-01-16 美商艾費尼T醫療公司 對新抗原具特異性之結合蛋白與工程化細胞及其用途
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
EP4573114A4 (en) * 2022-08-19 2026-07-29 Memorial Sloan Kettering Cancer Center T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
WO2024148178A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer
WO2024148181A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer
WO2024148185A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer
US20260216333A1 (en) * 2023-01-04 2026-07-30 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer
JP2026502557A (ja) * 2023-01-13 2026-01-23 コレジェネ バイオテクノロジー カンパニー リミテッド 抗原結合タンパク質およびその使用
CN121127257A (zh) * 2023-02-03 2025-12-12 Affini-T治疗有限公司 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法
IL304887A (en) * 2023-07-31 2025-02-01 Yeda Res & Dev T-cell receptor directed against RAS neoantigen
WO2025179050A2 (en) * 2024-02-21 2025-08-28 Biontech Us Inc. Vaccine compositions and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
IL106610A0 (en) 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20150104441A1 (en) * 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
SG10201913978RA (en) * 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
EP3286222A4 (en) 2015-03-23 2018-08-08 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
KR20180043800A (ko) 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
SG10201913868XA (en) * 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
AU2019321608B2 (en) 2018-08-16 2024-07-25 Biontech Us Inc. T cell receptor constructs and uses thereof

Similar Documents

Publication Publication Date Title
JP7803939B2 (ja) Kras変異に特異的t細胞受容体のスクリーニング及び抗腫瘍用途
US12297252B2 (en) T cell receptors with improved pairing
KR102809909B1 (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
Tran et al. T-cell transfer therapy targeting mutant KRAS in cancer
Yuan et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
IL268917B2 (en) A population-based immunogenic peptide identification platform
JP2019520591A5 (cg-RX-API-DMAC7.html)
JP2021535749A5 (cg-RX-API-DMAC7.html)
AU2016264623A1 (en) Shared neoantigens
CN113795585B (zh) T细胞受体及其使用方法
CN113906141B (zh) T细胞受体及其使用方法
CN113785065B (zh) T细胞受体及其使用方法
CN113785064B (zh) T细胞受体及其使用方法
WO2023099622A1 (en) Treatment
AU2022301201B2 (en) A method for identifying variants in gene products from gene constructs used in cell therapy applications
US20250163124A1 (en) T cell receptors with improved pairing
CN112375136A (zh) Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途
CA3229551A1 (en) Vaccine design pipeline
McKenzie et al. Aspects of cancer immunotherapy
ES3048639T3 (en) A modified hla-b57 with increased expression levels
CN116574748B (zh) 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
KR20200109768A (ko) T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
CA3239837A1 (en) Treatment
HK40089777A (en) Screening and antitumor use of kras mutation specific t cell receptor